Alyssa Llamas M.P.H.

Director

Education: B.S., University of California, San Diego; M.P.H., The George Washington University

562-207-8807
alyssa@wynnehealth.com

Alyssa Llamas has a diverse background in health policy and public health, with seven years of experience in government, research, and nonprofit settings, in health care access, women’s health, occupational safety and health, immunization, and environmental health.

Alyssa draws from her hands-on experience in advocacy, research, and policymaking to best serve clients. Most recently, she managed the federal policy portfolio at the National Women’s Health Network. At the Jacobs Institute of Women’s Health, Alyssa was first author of a white paper on the public health impacts of state-level abortion restrictions for policymakers, advocates, and the media. As an intern in the Health Office of the Senate Health, Education, Labor and Pensions Committee under Ranking Member Patty Murray, she provided legislative support to senior staff, performed background research on administration officials, and helped conduct committee hearings.

Through her frontline experience, Alyssa understands how federal policy decisions affect state and local partners and how to collaborate effectively with community members. Before graduate school, Alyssa spent five years with the Centers for Disease Control and Prevention (CDC), delivering public health services as a field assignee at the Rocky Mountain Tribal Epidemiology Center and the Idaho Department of Health and Welfare. She also worked at CDC’s National Institute for Occupational Safety and Health, developing education materials and implementing strategies to foster adoption of recommended best practices.

Alyssa received her Bachelor of Science degree from the University of California, San Diego and a Master of Public Health with a concentration in health policy from The George Washington University. Originally from California, she lives in Washington, D.C.

Washington Begins Horse Trading over Next Phase of COVID-19 Aid

California-Health-Care-Foundation 400x200
Negotiations in Congress over the next COVID-19 aid plan are expected to start after the July 4 break, and a package is likely to pass before Congress adjourns for the August recess. In total, we expect the bill to include up to $3 trillion in funding based on the House proposal, the HEROES Act. The Senate, House, and Trump administration proposals are starkly different, so the exact contents of the final legislation remain to be seen. The main political pull is essentially between those who want the aid to be mostly about funding economic recovery and those who would focus on boosting medical care and public health....
+ Read More

The Benefits of Telehealth During a Pandemic — and Beyond

Commonwealth-Fund 400x200
Medicare began including telehealth as a benefit nearly 20 years ago, but has used it only on a limited basis. This was in large part because of statutory restrictions that limited coverage to rural beneficiaries who received care by certain practitioners in designated sites, which did not include the beneficiary’s home. Now, in the wake of the COVID-19 outbreak, policymakers are looking to telehealth as critical to ensuring that Medicare beneficiaries can still access care while reducing the risk of coronavirus transmission....
+ Read More

You’re Doing It Wrong: What Changes In Medicaid And SNAP Reveal About The Trump Administration’s Investment In The Social Determinants Of Health

The Department of Health and Human Services (HHS) defines the social determinants of health as the “conditions in the environments in which people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks.” The concept, which comes from the global public health field, is at its best when it is understood to encompass an individual’s social location—their race, ethnicity, sex, class, ability, orientation, culture, and how each of these identities impact them in their community context. It was created to identify and serve the most vulnerable among the world’s populations and to address the inequities that disproportionately impact their lives and their health. ...
+ Read More

Five Reasons Medicare For All (Or Anything Like It) Won’t Pass In 2021

While conventional wisdom, and some presidential candidates, have already begun to temper these expectations, my goal here is to document five reasons why Medicare for All (M4All), Medicare buy-in, or federal public option legislation cannot pass in the near future. My hope, in doing so, is that we Democrats spare ourselves the precious time, internal acrimony, and political fallout that Republicans faced when their lofty ACA repeal promises went unfulfilled....
+ Read More

CMS Releases Advance Notice For Medicare Advantage And Part D Plans

Last week, the Centers for Medicare & Medicaid Services (CMS) released Part II of its Advance Notice of Methodological Changes for Medicare Advantage (MA) Capitation Rates and Part D Payment Policies for Calendar Year (CY) 2021 (fact sheet). The agency also released its proposed rule on policy and technical changes to MA and Part D for CYs 2021 and 2022 (fact sheet). A press release for both developments is available here. This post focuses on summarizing the Advance Notice component of this package of policies....
+ Read More

The Forecast for Legislative and Regulatory Activity on Health Care in 2020

As the impeachment trial has concluded with the acquittal of President Trump, Congress is now returning to some sense of normalcy. On the health care front, policymakers will need to secure a deal relatively quickly on top-priority issues like prescription drug pricing and surprise medical billing. The apparent deadline for final legislation in both regards is the May 22 expiration date of funding for several public health programs (e.g., community health centers), which many are eyeing as the last real opportunity for meaningful reform this year. Many doubt whether Congress will produce much after that date because of compressed schedules to accommodate party conventions and an extended recess in October. However, health care is in the forefront of voters’ minds. ...
+ Read More

New Legislation to Control Drug Prices: How Do House and Senate Bills Compare? An Update

Commonwealth-Fund 400x200
As Congress grapples with an evolving impeachment inquiry, lawmakers have remained focused on lowering prescription drug costs. In December, the House passed the Elijah E. Cummings Lower Drug Costs Now Act (H.R. 3) by a 230–192 vote, largely along party lines with no Democratic defections. House Democratic leaders successfully assuaged grumblings from the Congressional Progressive Caucus that H.R. 3 did not go far enough by doubling the minimum number of drugs subject to price negotiation, among other policy changes....
+ Read More

Surprise Medical Billing Might Get a Hybrid Solution

California Health Care Foundation Logo
Reaching a consensus on how to protect patients from surprise medical bills has eluded Congress for most of the year even though members in both parties and chambers are highly motivated to find a fix. With an agreement reached over the December 7–8, 2019, weekend, a solution seems closer than it has in a long time....
+ Read More

A Look Inside The Hospital Transparency Final Rule

On November 15, 2019, The Centers for Medicare & Medicaid Services (CMS) finalized a controversial set of requirements for the disclosure of hospital pricing data to degrees heretofore not seen. Stemming from the recent transparency Executive Order (EO), the final rule reflects the current administration’s overall push to increase pricing and cost transparency throughout the health care system. While the original proposal faced substantial backlash from stakeholders, CMS’ final decision is nearly identical to what the agency originally proposed....
+ Read More

New Legislation to Control Drug Prices: How Do House and Senate Bills Compare?

Commonwealth-Fund 400x200
The following tables compare H.R. 3 based on the legislative text advanced by key committees of jurisdiction and key provisions of related proposals: the Prescription Drug Pricing Reduction Act of 2019 (S. 2543), advanced by the Senate Finance Committee in July; and the Advanced Notice of Proposed Rulemaking (ANPRM): Medicare Program, IPI Model for Medicare Part B Drugs, issued by the Centers for Medicare and Medicaid Services last October....
+ Read More